Patient Management

Study Highlights High Early Mortality in Multiple Myeloma, Especially Among Older, Male, and Minority Patients

Early mortality (EM) is a concern in hematologic malignancies, including multiple myeloma (MM), where mortality rates remain high within the first two years of diagnosis. Despite advances in...
CURATED BY: Danielle Roberts,
MS, MMSc, PA-C
Read More
Picture of Danielle Roberts,
Danielle Roberts,
MS, MMSc, PA-C
Associate Chief of Education, Winship Cancer Institute of Emory University

Patient Management Guidelines

National Comprehensive Cancer Network Clinical Practice Guidelines

The National Comprehensive Cancer Network Clinical Practice Guidelines has evidence-based guidance on the diagnosis, workup, and management of multiple myeloma.
Read More >

EHA-ESMO Clinical Practice Guidelines

These guidelines provide recommendations on treatment for both patients who are newly diagnosed with multiple myeloma and patients who have relapsed/refractory disease, plasma cell leukemia, solitary plasmacytoma, and smoldering myeloma.
CURATED BY:
Larisa A. Gallo,
DMSc, PA-C
Read More >

Stratification for Myeloma and Risk-Adapted Therapy

The Mayo Clinic offers information on a guide for the treatment of patients with multiple myeloma.
Read More >

Articles

CAR T Cells Transform Treatment for Relapsed B Cell Malignancies, Offering Hope for Durable Remissions

Chimeric antigen receptor (CAR) T cells, engineered to target tumor-specific antigens, have revolutionized treatment for relapsed or refractory B cell malignancies. CAR T cells targeting CD19, a protein expressed on...
CURATED BY:
Jill N. Burke,
CNP, DipACLM
Read More >

Supportive Care Key to Managing Side Effects in Multiple Myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy in the United States. Advances in treatments such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and stem cell transplants have...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN
Read More >

Serial Measurable Residual Disease Monitoring Found to Improve Prognosis and Treatment in Multiple Myeloma

Measurable residual disease (MRD) status is a critical prognostic indicator in both newly diagnosed and relapsed multiple myeloma (MM), with persistent MRD linked to poorer survival outcomes....
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN
Read More >

Guidelines Highlight Symptom Management and Nurse Roles in Multiple Myeloma Care

Many patients with multiple myeloma (MM) suffer from symptoms like fatigue, diarrhea, peripheral neuropathy, and pain, despite treatment efforts. Factors such as age, comorbidities, and medication side effects increase their...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN
Read More >

COVID-19 Vaccine Response in Patients With Multiple Myeloma and Waldenström Macroglobulinemia

Patients with multiple myeloma (MM) and Waldenström macroglobulinemia (WM) often have impaired immune responses, raising concerns about the effectiveness and durability of COVID-19 vaccines in these populations. Researchers of a...
CURATED BY:
Jill N. Burke,
CNP, DipACLM
Read More >

Study Evaluates Feasibility of Group-Based Multiple Myeloma Survivorship Intervention

Researchers of a recent study aimed to evaluate the feasibility and preliminary effectiveness of a novel multidisciplinary group-based multiple myeloma survivorship intervention. This mixed-method, repeated measures feasibility study involved seven...
CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C
Read More >
Load More

Privacy Policy
Terms of Use

Company
Contact

Partner with Us
Ambassador Program

© 2024 Point of Care Network, LLC. All Rights Reserved.

Privacy Policy
Terms of Use
Company
Contact
Partner with Us
Ambassador Program

© 2024 Point of Care Network, LLC. All Rights Reserved.

Share